Some Black women with hormone receptor (HR)-positive/HER2-negative breast cancer had worse outcomes compared with White women despite having similar genetic recurrence risk scores, according to data from the 2022 San Antonio Breast Cancer Symposium. Yara Abdou, MD, assistant professor at the University of North Carolina at Chapel Hill and Lineberger Comprehensive Cancer Center, presented results of an analysis of clinical outcomes respective to race and ethnicity in women enrolled in the RxPONDER trial. The trial aimed to assess the value of the 21-gene recurrence score (RS) in patients with ...
SABCS 2022
The San Antonio Breast Cancer Symposium (SABCS) is the largest and most prestigious scientific gathering on breast cancer research. Topics cover new treatments, patient care, surgical and reconstructive techniques, health equity, telemedicine, and more. Find highlights from the sessions that are most relevant to oncology nurses.
Advertisement
Results from the DESTINY-Breast03 study indicate survival advantage with the antibody drug conjugate.
The local recurrence rates were optimistic for women with multiple ipsilateral breast cancer in one clinical trial.
Advertisement
A group of nurses led development of a symptom management mobile app for patients recovering from breast surgery.
Oncology nurses play a vital role in identifying the signs of treatment-related angiosarcoma during survivorship care.
Melissa Rosen, MA, explains how advanced practitioners can help connect patients with the organization and its resources.
Sanita Burgic, MSN, APRN, AGNP-C, discusses key takeaways from her JADPRO Live presentation on updates in breast cancer.
The study explored outcomes of CBT and how it can help reduce disease burden for female patients with breast cancer.
TROPiCS-02 study data shows that sacituzumab govitecan improves overall survival for HR+/HER2- metastatic breast cancer.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.